EntreMed

Precision Therapeutics changes name to Helomics, reorganizes management

Friday, November 14, 2014 10:51 AM

Precision Therapeutics has changed its name to Helomics, a Pittsburgh, Pa.-based, privately held comprehensive personalized healthcare company that develops next-generation diagnostics for the oncology field.

More... »


EntreMed stockholders approve name change to CASI Pharmaceuticals

Friday, June 13, 2014 01:13 PM

EntreMed, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, said its annual meeting of stockholders voted in favor of changing the company's corporate name to CASI Pharmaceuticals. The name change will occur June 16, with the rollout of a new web site, www.casipharmaceuticals.com.

More... »


EntreMed announces changes to board of directors, CEO appointment

Friday, April 5, 2013 12:05 PM

The board of directors of EntreMed, a clinical-stage pharmaceutical company focused on cancer, has appointed two new individuals as directors. Joining the board are James Huang and Y. Alexander Wu, Ph.D.

More... »

EntreMed initiates phase II trial in advanced/metastatic soft tissue sarcoma

Friday, January 25, 2013 01:11 PM

EntreMed, a clinical-stage pharmaceutical company, has initiated a single-center phase II study of oral ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.

More... »

EntreMed appoints Ren as interim CEO

Wednesday, April 4, 2012 12:43 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Dr. Ken K. Ren as interim CEO, effective April 2, 2012.

More... »

EntreMed names two to board of directors

Tuesday, February 7, 2012 01:07 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Wei-Wu He, Ph.D, executive chairman of its board of directors, and Tak W. Mak, Ph.D, as member of the board of directors.

More... »

CenterWatch Data Library
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs